Aligos Therapeutics (ALGS) Return on Invested Capital (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Return on Invested Capital for 5 consecutive years, with 0.08% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Return on Invested Capital rose 838.0% year-over-year to 0.08%, compared with a TTM value of 0.08% through Dec 2025, up 838.0%, and an annual FY2025 reading of 0.41%, up 242.0% over the prior year.
- Return on Invested Capital was 0.08% for Q4 2025 at Aligos Therapeutics, up from 1.0% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.08% in Q4 2025 and bottomed at 8.46% in Q4 2024.
- Average Return on Invested Capital over 5 years is 1.48%, with a median of 1.0% recorded in 2025.
- The sharpest move saw Return on Invested Capital tumbled -725bps in 2024, then skyrocketed 838bps in 2025.
- Year by year, Return on Invested Capital stood at 0.64% in 2021, then plummeted by -35bps to 0.86% in 2022, then plummeted by -40bps to 1.21% in 2023, then crashed by -599bps to 8.46% in 2024, then surged by 99bps to 0.08% in 2025.
- Business Quant data shows Return on Invested Capital for ALGS at 0.08% in Q4 2025, 1.0% in Q3 2025, and 0.72% in Q2 2025.